At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
0.01% concentration atropine dropsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Side Effects of Atropine (SEA) Study
In Brief
A Phase 2 clinical trial evaluating 0.01% concentration atropine drops for Myopia. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study will perform several objective and subjective measurements of the eye and vision before and after a week of using 0.01% concentration atropine drops. These measurements will help to obtain a comprehensive understanding of the side effects of this concentration of atropine and determine if the drops would be tolerated as a possible preventative treatment for nearsightedness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJul 2018
Primary CompletionJan 2019
TodayJul 2026
First PostedJul 19, 2018
Enrollment StartJul 23, 2018
Primary CompletionJan 17, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.0 years ago
Interventions
0.01% concentration atropine dropsdrug
One drop of 0.01% concentration atropine in each eye at night for seven days.